Restart Life Introduces BrainQ(TM) - A Wholly Owned Brand
Vancouver, British Columbia--(Newsfile Corp. - June 11, 2025) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to introduce BrainQ™, a wholly owned brand developed by the Company. The first product under the BrainQ™ brand will be the BrainQ™ Healthy Cereal, which follows the product line established by the highly anticipated BrainBalls™ in cereal form.BrainQ™ Healthy Cereal will be produced in collaboration with the Company's established co-packing partner in British...
2025-06-11 8:00 AM EDT
Restart Life Introduces BrainBalls(TM) Product Line
Vancouver, British Columbia--(Newsfile Corp. - June 5, 2025) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to announce the forthcoming launch of BrainBalls™, a functional wellness snack developed in collaboration with Brain Balls Inc. through a strategic joint venture established in December 2024. BrainBalls™ represents the first consumer-facing product to emerge from this partnership and exemplifies Restart Life's dedication to advancing wellness-oriented solutions for the modern consumer. Since forming...
2025-06-05 8:00 AM EDT
Restart Life Expands Intellectual Property Through Trademark Licensing Agreement
Vancouver, British Columbia--(Newsfile Corp. - March 17, 2025) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSD) ("Restart Life" or the "Company") is pleased to announce that it has secured the licensing rights to health-related trademarks, a strategic move that will play a role in the Company's future brand development initiatives. This agreement aligns with Restart Life's efforts to strengthen its market position and expand its product portfolio.Restart Life has secured an exclusive license to use four...
2025-03-17 8:00 AM EDT
Restart Life Secures Strategic Production Partner
Vancouver, British Columbia--(Newsfile Corp. - February 19, 2025) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSD) ("Restart Life" or the "Company") is pleased to announce that the Company has secured a strategic production partnership with a Canadian co-packer. This new strategic partnership follows the press release dated December 13, 2024, where Restart Life and Brain Balls Inc. formed a Joint Venture to bring health-focused products to market, targeting cognitive performance, mental clarity, and overall brain health.With...
2025-02-19 9:00 AM EST
Restart Life Announces Key Business Updates
Vancouver, British Columbia--(Newsfile Corp. - February 13, 2025) - Restart Life Science Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSD) ("Restart Life" or the "Company") is pleased to provide an update on recent developments under the leadership of its newly appointed CEO. Steve Loutskou, a serial entrepreneur, is dedicated to driving shareholder value through sustainable growth and expanding opportunities for the Company."I would like to thank our shareholders for their support in our private placement which closed on February 7th,...
2025-02-13 9:00 AM EST
Restart Life Sciences Corp. Relies on Exception Under CSE Policy 4.6(2)(b) for Previously Closed Private Placement and Debt Settlement Transactions and Announces Debt Settlement Transaction
Vancouver, British Columbia--(Newsfile Corp. - February 7, 2025) - Restart Life Science Corp. (CSE: HEAL) (FSE: HN3) (OTC Pink: NMLSD) ("Restart Life" or the "Company") announces that the Company proposes to enter into debt settlement agreements with certain creditors (the "Creditors") to settle up to CAD$120,000 in debt (the "Debt Settlement").Pursuant to the Debt Settlement, the Company shall issue units (the "Units") at a price of $0.075 per Unit. Each Unit will consist of one common share in the...
2025-02-07 5:15 PM EST
Nova Mentis Assigns Intellectual Property
Vancouver, British Columbia--(Newsfile Corp. - August 27, 2024) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company") is pleased to announce it has entered into an intellectual property conveyance agreement (the "Agreement") with Ludwig Enterprises Inc. ("LUDG") and Dr. Marvin S. Hausman ("Hausman"), CEO of Ludwig, pursuant to which the Company shall assign to Ludwig all of its intellectual property and patent of the mRNA Neuro Panel and Serotonin Assay, along with any...
2024-08-27 9:00 AM EDT
Nova Mentis Announces Change of Directors
Vancouver, British Columbia--(Newsfile Corp. - February 26, 2024) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company") announces the appointment of Steve Loutskou to the Company's Board of Directors, effective February 23, 2024.Mr. Loutskou, a seasoned serial entrepreneur, boasts a career spanning over 20 years, marked by numerous success stories. From the initiation of early-stage start-ups to steering them through mature commercialization phases, he has demonstrated exceptional skills in navigating the intricate landscape...
2024-02-26 8:30 AM EST
Nova Mentis Applauds Government Decision to Create Rare Disease Advisory Group
Vancouver, British Columbia--(Newsfile Corp. - November 3, 2023) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased the Canadian government has established a new Implementation Advisory Group (IAG) for drugs for rare diseases, as part of its National Strategy to help facilitate information sharing and improve access and affordability of effective drugs for rare diseases...
2023-11-03 8:30 AM EDT
Nova Mentis Announces Participant Screening Underway in Canada's First Psilocybin Clinical Trial for Fragile X Syndrome
Vancouver, British Columbia--(Newsfile Corp. - August 30, 2023) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to provide an update on its Phase IIA clinical trial testing psilocybin for the treatment of fragile X syndrome (FXS), the leading genetic cause of autism spectrum disorder (ASD).The research team is continuing its recruitment efforts and has...
2023-08-30 8:30 AM EDT
Nova Mentis to Enter mRNA AI Diagnostics Business
Vancouver, British Columbia--(Newsfile Corp. - April 26, 2023) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce the launch of SwabAi Diagnostics Inc. (SwabAi). On June 16, 2022, NOVA filed a patent titled "Diagnosing, Monitoring and Treating Neurological Disease With Psychoactive Tryptamine Derivatives and mRna Measurements." The Company intends to unleash the full...
2023-04-26 8:30 AM EDT
Nova Mentis Begins Recruitment in First-of-its-Kind Health Canada Psilocybin Trial
Vancouver, British Columbia--(Newsfile Corp. - April 18, 2023) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce that it has begun recruiting participants into the first-ever clinical trial investigating the effects of psilocybin on the cognitive and behavioural symptoms associated with fragile X syndrome (FXS), the leading genetic cause of autism spectrum disorder...
2023-04-18 8:30 AM EDT
Nova Mentis Receives Institutional Review Board Approval to Commence Psilocybin Clinical Trial
Vancouver, British Columbia--(Newsfile Corp. - April 11, 2023) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce it has received institutional review board (IRB) approval in Canada to begin its human study testing the efficacy of psilocybin on adults diagnosed with fragile X syndrome (FXS), the leading genetic cause of autism spectrum disorder...
2023-04-11 8:30 AM EDT
Nova Mentis Provides Corporate Update and 2023 Outlook
Vancouver, British Columbia--(Newsfile Corp. - April 5, 2023) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to provide a corporate update, including planned catalysts for 2023. "NOVA executed on several key research and drug development milestones in 2022, which has set the stage for a meaningful 2023. Our focus remains on advancing our proprietary...
2023-04-05 8:30 AM EDT
Novel Therapeutic Solutions are Needed as Autism Rates Increase
Vancouver, British Columbia--(Newsfile Corp. - March 29, 2023) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is highlighting the importance of developing new therapeutic solutions for autism spectrum disorder (ASD) following a new study showing autism is on the rise among young children.The report from the Centers for Disease Control and Prevention (CDC) in the United...
2023-03-29 8:30 AM EDT
Nova Mentis Granted Health Canada Section 56 Exemption to Begin Psilocybin Clinical Trial
Vancouver, British Columbia--(Newsfile Corp. - February 14, 2023) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce it has received an exemption under Section 56 of the Controlled Drugs and Substances Act allowing the Company to proceed with the first-ever Phase IIA clinical trial assessing repetitive, oral microdose psilocybin therapy for fragile X...
2023-02-14 8:30 AM EST
Nova Mentis Appoints Derek Ivany as Executive Chairman
Vancouver, British Columbia--(Newsfile Corp. - January 18, 2023) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce the appointment of Derek Ivany to the position of Executive Chairman. In this new role, Mr. Ivany's mandate will include specific focus on corporate development outreach, mergers and acquisitions, capital markets support and other strategic value...
2023-01-18 8:30 AM EST
Nova Mentis Receives Health Canada Approval for First-Of-Its-Kind Psilocybin Clinical Trial
Vancouver, British Columbia--(Newsfile Corp. - December 22, 2022) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is proud to announce that the company has received a No Objection Letter from Health Canada, allowing NOVA to proceed with the first-ever Phase II A clinical trial assessing repetitive, oral microdose psilocybin therapy for fragile X syndrome (FXS), the...
2022-12-22 12:21 PM EST
Nova Mentis' Psilocybin Preclinical Study Published in International Science Journal
Vancouver, British Columbia--(Newsfile Corp. - December 8, 2022) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce that its psilocybin preclinical study has been published in the Journal of Psychopharmacology, a fully peer-reviewed, international science journal.The article titled 'Psilocybin mitigates the cognitive deficits observed in a rat model of Fragile X syndrome' highlights...
2022-12-08 8:30 AM EST
Nova Submits Phase II A Psilocybin Clinical Trial Application to Health Canada
Vancouver, British Columbia--(Newsfile Corp. - November 30, 2022) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is proud to announce that the company has submitted to Health Canada the first-ever Phase II A clinical trial application (CTA) testing the safety and efficacy of oral microdose psilocybin therapy for fragile X syndrome (FXS), the leading genetic cause...
2022-11-30 8:30 AM EST